FISCHER CHEMIC LTD.

Fischer Medical Ventures Ltd has announced that its Board of Directors will convene on November 14, 2026, via video conferencing. The primary agenda items include the consideration and approval of the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. Additionally, the board will address any other matters as specified in the agenda. The company also reiterated that the trading window for its equity shares remains closed for designated persons and related parties until 48 hours after the declaration of these financial results.

Fischer Medical Ventures Limited announced the appointment of Mr. Chan Sing En as an Independent Director to the Board of Directors of its material wholly owned subsidiary, FMV Global Innovations Pte. Ltd., Singapore. The appointment is effective from October 27, 2026. Mr. Chan Sing En brings over three decades of experience in private equity, corporate finance, and operational turnarounds across Southeast Asia and Australia. He currently serves as Principal and Director of SovCapital Pte Ltd and is on the advisory board of FTAG Investment Bank. He is not related to any directors of Fischer Medical Ventures and is not debarred from holding a directorship.

Fischer Medical Ventures Ltd announced that its wholly-owned material subsidiaries have declared significant dividends. Time Medical International Ventures (India) Private Limited declared a dividend of ₹6.5 crore for the financial year ended March 31, 2026. FlynnCare Health Innovations Private Limited declared a dividend of ₹10 crore for the same fiscal year. Additionally, FMV Global Innovation Pte Limited, another wholly-owned material subsidiary, approved an interim dividend of USD 1.1 million for the year ended March 31, 2027. These declarations were made at their respective Annual General Meetings or Board Meetings.

Fischer Medical Ventures Ltd has issued a corrigendum to its Annual Report for the financial year 2025-26, which was previously despatched to shareholders on September 7th, 2026. The company is rectifying several inadvertent errors and omissions across various sections of the report. These corrections include updates to financial highlights, auditor's reports (UDIN), paid-up equity share capital, and tables related to financial risk management, foreign currency exposure, and maturity analysis of assets and liabilities. The revised Annual Report, incorporating these changes, is attached for stakeholders' reference. The company is focused on its 'Next Phase of Innovation-Led Growth', aiming to scale its imaging portfolio and healthcare technologies.

Fischer Medical Ventures Ltd has announced the closure of its trading window for Promoters, Directors, and Designated Persons. This closure will be effective from October 1, 2026, and will continue until 48 hours after the declaration of the Un-Audited Financial Results for the quarter ended September 30, 2026. The company will separately inform the stock exchanges about the board meeting scheduled to approve these financial results. Designated persons and their immediate relatives are prohibited from trading in the company's securities during this period.

Fischer Medical Ventures Ltd's Board of Directors approved rights issues by its material unlisted subsidiaries: Time Medical International Ventures (India) Private Limited, Flynncare Health Innovations Private Limited, and FMV Global Innovation Pte. Ltd. The company will also invest in these rights issues. Time Medical issued 15,603 shares at ₹7,370.25 each, Flynncare issued 1,507 shares at ₹82,943.48 each, and FMV Global issued 53 shares at ₹48,83,552.64 each. The total investment by Fischer Medical Ventures in Time Medical is INR 11,50,00,000.

Fischer Medical Ventures Ltd has issued a revised presentation for its investor/analyst call held on September 7, 2026. The presentation, originally dated September 7, 2026, details the company's integrated AI-enabled healthcare platform. This platform spans medical imaging, population-scale screening, hospital digitization, and analytics, aiming to build the world's largest Healthcare AI Solutions Platform. The company emphasizes its proprietary AI imaging technology, a comprehensive diagnostic portfolio, and a unified clinical + analytics architecture. The presentation also outlines its strategic ecosystem, including partnerships with Time Medical and FlynnCare, and its global scalability across various regions. A legal disclaimer highlights the informational nature of the memorandum and associated risks.

Fischer Medical Ventures Ltd has released its Chairman's Letter to Shareholders, detailing significant business developments and future outlook. The company has expanded its portfolio beyond imaging hardware to include point-of-care diagnostics, AI-enabled healthcare software, and drug discovery initiatives. Its business is now organized into three segments: Radiology, Preventive Healthcare, and Wellness Solutions. The Radiology segment, its largest, focuses on Diagnostics, Screening, and Interventional Radiology, featuring proprietary imaging technology. Key products like the AURIX (0.35T) and AURA (0.7T) open MRI systems are highlighted for their cost-effectiveness and advanced features, with global market expansion underway. The company also details its closed MRI systems (MICA/MICA Smart, QUIN) and neonatal MRI (NEONA), alongside its CT scanner range (CLARION).

Fischer Medical Ventures Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26. The report details the company's corporate identity, business activities, operational footprint, and employee statistics. Fischer Medical Ventures operates in the manufacturing and trading of medical devices and software, contributing 100% to its turnover. The company serves both national and international markets across 9 states and 7 countries, primarily through a B2B model targeting diagnostic centers, hospitals, and healthcare institutions. The BRSR filing also includes data on employee demographics, with a total of 19 permanent employees as of FY26, and notes the absence of assurance providers for the report.

Fischer Medical Ventures Limited has published its 33rd Annual Report for the financial year 2025-2026. The report details the company's 'Next Phase of Innovation-Led Growth,' highlighting achievements such as crossing ₹100 crore in consolidated revenue and gaining trust from radiologists for its MRI platforms. The company, headquartered in Vizag, operates in magnetic resonance imaging (MRI), computed tomography (CT), digital radiography, AI-powered preventive healthcare, advanced wound care, and digital health technologies. The report is available on their website and outlines strategic initiatives for scaling their imaging portfolio, accelerating technology pipelines, expanding market reach, and strengthening manufacturing capabilities. Forward-looking statements are included with a disclaimer regarding inherent risks and uncertainties.